Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Operating Activities:    
Net loss $ (3,269) $ (3,707)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on warrants [note 4 and note 5 [f]] (52) (667)
Depreciation 93 56
Stock-based compensation [note 5 [c] and note 5 [d]] 211 468
Restructuring gain [note 8] (98)  
Changes in operating assets and liabilities:    
Interest receivable 32 58
Amounts receivable 241 (219)
Prepaid expenses and other assets 189 401
Accounts payable (1,762) (751)
Accrued liabilities other (1,510) 268
Accrued clinical liabilities (3,073) (1,516)
Accrued compensation 22 (523)
Lease obligation (19) (14)
Deferred collaboration revenue [note 3]   (2,941)
Net cash used in operating activities (8,995) (9,087)
Financing Activities:    
Taxes paid related to net share settlement of equity awards (19)  
Net cash used in financing activities (19)  
Investing Activities:    
Purchase of investments (5) (24,169)
Proceeds from maturities of investments 9,475 17,859
Purchase of property and equipment (1)  
Net cash provided by (used in) investing activities 9,469 (6,310)
Effect of exchange rate changes on cash 2  
Net increase (decrease) in cash and cash equivalents 457 (15,397)
Cash and cash equivalents at beginning of period 15,233 34,310
Cash and cash equivalents at end of period $ 15,690 $ 18,913